foldam
chemistri
initi
profound
chang
biopolym
mimicri
last
year
show
isol
stabl
secondari
structur
element
creat
varieti
oligomer
backbon
either
close
eg
aliphat
band
gpeptid
oligom
nalkyl
glycin
peptoid
beyond
eg
mphenylen
ethynylen
oligom
aromat
oligoamid
natur
biopolym
biopolym
fold
function
intim
link
reason
sequencebas
biopolym
mimicri
foldam
provid
uniqu
use
tool
studi
biolog
complementari
convent
chemic
approach
may
lead
downstream
applic
novel
diagnostictherapeut
agent
divers
monom
unit
biopolym
amino
acid
nucleotid
limit
evolutionari
pressur
case
foldam
chemistri
research
creativ
allow
entir
new
chemic
space
explor
beyond
lipinski
criteria
identif
foldam
recogn
specif
biopolym
target
certainli
facilit
control
exert
monom
sequenc
secondari
structur
mani
synthet
fold
oligom
well
divers
build
block
repertoir
substitut
pattern
side
chain
backbon
isoster
consider
expand
two
decad
howev
task
remain
extrem
challeng
current
level
knowledg
still
foldamerbas
approach
faith
mimic
protein
secondari
structur
element
engag
bind
event
routin
avail
highli
modular
chemistri
synthesi
higher
order
foldam
architectur
access
structur
complex
target
biomolecul
design
foldam
atom
resolut
well
comput
design
approach
need
facilit
process
lead
discoveri
potent
foldamerbas
modul
biomolecular
interact
substanti
progress
achiev
direct
cover
follow
section
next
frontier
foldam
medicin
chemistri
certainli
lie
vivo
applic
improv
resist
proteolysi
demonstr
number
foldam
backbon
signific
advantag
translat
increas
durat
action
current
effort
meet
challeng
focu
cellular
uptak
properti
foldam
approach
improv
cell
permeabl
design
engag
intracellular
target
therapeut
relev
well
pharmacokinet
pk
properti
bioavail
today
foldam
repres
rapidli
grow
ensembl
molecul
term
divers
chemic
complex
popul
new
larg
empti
area
chemic
space
highli
complementari
small
molecul
biolog
foldam
classifi
accord
chemic
natur
backbon
either
fulli
aliphat
eg
b
gpeptid
peptoid
peptidomimet
oligourea
base
aromat
unit
eg
oligoarylor
heteroarylamid
result
combin
two
fig
helic
far
wide
found
structur
motif
among
foldam
even
though
exampl
bstrand
bsheet
found
literatur
wherea
mani
foldam
backbon
exhibit
robust
highli
predict
conform
other
show
strong
conform
prefer
induc
fold
upon
bind
target
mimic
secondari
structur
element
base
rigid
extend
backbon
repres
anoth
class
conceptu
differ
molecul
fold
like
natur
secondari
structur
element
intend
mimic
rather
minim
scaffold
design
project
right
function
group
proper
orient
achiev
molecular
recognit
process
section
briefli
review
foldam
system
develop
context
medicin
chemistri
applic
particular
focu
foldam
studi
aqueou
solut
particularli
relev
biolog
studi
larg
number
biolog
process
cellular
commun
program
cell
death
involv
interact
protein
anoth
biopolym
eg
protein
nucleic
acid
lipid
carbohydr
ahel
domain
largest
class
secondari
structur
element
protein
play
major
role
interact
roughli
proteinprotein
complex
protein
data
bank
possess
ahel
interfac
accord
recent
statist
analysi
henc
artifici
helic
scaffold
intend
mimic
sidechain
display
ahelic
present
interfac
import
pharmaceut
interest
helic
fold
aliphat
oligom
contain
proteinogen
side
chain
classifi
biotic
helic
usual
differ
number
methylen
unit
saturatedunsatur
bond
backbon
well
natur
bond
connect
unit
amid
urea
hydrazid
sidechain
substitut
pattern
fig
helic
conform
gener
character
specif
hydrogenbond
network
handed
respect
orient
backbon
hbond
donor
acceptor
group
determin
result
macrodipol
protein
helic
righthand
atom
hydrogenbond
ring
helic
ahelic
respect
bpeptid
backbon
amino
acid
residu
homolog
one
addit
methylen
unit
compar
apeptid
side
chain
case
monosubstitut
bamino
acid
residu
lie
next
carboxyl
amin
function
group
b
b
peptid
respect
bpeptid
form
depend
substitut
pattern
stereochemistri
side
chain
along
backbon
well
use
cyclic
acycl
monom
among
describ
bpeptid
helic
conform
best
studi
helix
stabil
hbond
pseudor
nh
c
approxim
residu
per
turn
follow
pioneer
work
seebach
b
substitut
residu
wide
use
due
straightforward
synthesi
mainli
via
homolog
natur
aamino
acid
high
propens
form
conform
concurr
appella
et
al
shown
format
even
favor
one
constrain
achc
acid
bresidu
incorpor
howev
cyclic
bresidu
switch
fivememb
ring
cycloalkan
acpc
carboxyl
acid
tightli
wound
obtain
use
gbranch
b
residu
also
shown
fulli
compat
format
bpeptid
compos
sequenc
altern
b
b
residu
howev
adopt
helic
conform
well
b
peptid
consist
residu
altern
chiral
multipl
report
bpeptid
abil
form
stabl
helic
conform
water
macrodipol
partial
neg
charg
nterminu
partial
posit
charg
cterminu
helix
stabil
charg
residu
interact
favor
macrodipol
electrostat
interact
lead
salt
bridg
opposit
charg
side
chain
residu
also
use
drive
helix
format
altern
constrain
cyclic
bamino
acid
residu
well
classic
sidechain
crosslink
approach
use
increas
helix
content
bpeptid
aqueou
solut
approach
exploit
attempt
design
helic
bpeptid
recogn
variou
protein
interfac
gpeptid
gamino
acid
residu
contain
three
backbon
carbon
atom
amino
carbonyl
group
result
gpeptid
less
studi
correspond
bpeptid
one
reason
addit
homolog
reduc
number
potenti
hydrogen
bond
increas
flexibl
whole
chain
howev
shown
simultan
seebach
hanessian
gpeptid
obtain
doubl
homolog
natur
aamino
acid
adopt
helic
conform
solut
stabil
hydrogenbond
ring
possess
screw
sens
polar
ahelix
disubstitut
g
peptid
well
trisubstitut
g
peptid
also
investig
could
reduc
number
access
conform
effect
stabil
fold
conform
chosen
appropri
rel
configur
stabl
conform
form
compar
correspond
g
peptid
compar
pure
gpeptid
helic
receiv
much
attent
bpeptid
counterpart
rel
studi
investig
possibl
use
context
biolog
applic
aliphat
n
n
link
oligourea
azaanalog
gpeptid
ch
substitut
nh
addit
nitrogen
atom
act
rigidifi
element
sinc
allow
format
threecent
hbond
network
oligourea
adopt
stabl
helic
fold
similar
g
peptid
presenc
hbond
ring
detail
nmr
cd
studi
well
xray
diffract
analys
conduct
guichard
group
type
foldam
understand
conform
behavior
four
five
urea
residu
need
initi
helic
fold
lowpolar
solvent
helic
proven
larg
unaffect
natur
side
chain
use
make
foldam
highli
robust
tunabl
watersolubl
oligourea
also
demonstr
abil
form
stabl
helix
maintain
aqueou
solut
even
fold
propens
weaker
design
mainli
inspir
sequenc
bioactiv
peptid
foldam
show
interest
activ
mimic
host
defens
cellpenetr
peptid
cpp
remain
seen
whether
homooligourea
relat
oligoureapeptid
chimera
could
also
serv
scaffold
design
inhibitor
proteinprotein
interact
ppi
peptoid
polynsubstitut
glycin
analog
apeptid
side
chain
shift
acarbon
nitrogen
amid
function
propens
peptoid
form
stabl
helic
despit
lack
hydrogenbond
network
report
zuckermann
group
shortli
discoveri
bpeptid
absenc
chiral
center
acarbon
peptoid
backbon
compens
helic
control
use
chiral
branch
side
chain
select
posit
along
sequenc
absenc
hbond
donor
group
fold
behavior
type
foldam
larg
govern
cistran
isomer
tertiari
amid
result
conform
share
similar
polyprolinetypei
helix
watersolubl
oligopeptoid
nscenscensp
sequenc
nsce
n
glycin
nspe
n
glycin
synthes
zuckermann
group
shown
adopt
stabl
righthand
helix
cisamid
bond
resist
peptoid
secondari
structur
solvent
environ
thermal
perturb
proven
type
helic
structur
stabil
steric
factor
heterogen
backbon
peptidefoldam
chimera
heterogen
backbon
foldam
oligom
contain
least
two
differ
type
monom
specif
fold
pattern
depend
backbon
composit
well
sidechain
sequenc
two
variabl
independ
alter
particular
combin
unnatur
monom
includ
abiot
one
natur
aamino
acid
proven
extrem
use
creat
unnatur
backbon
new
fold
pattern
molecular
recognit
properti
numer
exampl
report
introduct
unnaturalresidu
sequenc
bring
addit
level
conform
control
form
specif
secondari
structur
new
way
arrang
side
chain
space
wherea
aamino
acid
residu
provid
sidechain
divers
low
cost
thu
limit
number
noncanon
build
block
prepar
two
differ
strategi
envis
either
discret
replac
aamino
acid
along
sequenc
usual
follow
regular
pattern
alter
block
strategi
distinct
block
contain
specif
backbon
combin
togeth
ie
block
cofoldam
abpeptid
mix
aand
bresidu
variou
pattern
among
best
studi
chimer
oligom
first
studi
conduct
independ
zerb
reiser
gellman
group
altern
abpeptid
ie
ababab
repeat
pattern
group
shown
homochir
heterogen
backbon
adopt
helic
conform
preorgan
cyclic
subunit
need
helix
stabil
polar
solvent
mani
pattern
eg
ab
pattern
sinc
explor
found
lead
helic
structur
quit
close
ahelic
gellman
group
sinc
demonstr
util
approach
mimick
ahelic
extend
biolog
relev
natur
sequenc
abpeptid
contain
around
bresidu
evenli
dispers
along
backbon
provid
effect
ahelix
mimic
bind
affin
protein
surfac
similar
cognat
apeptid
ligand
despit
addit
atom
backbon
see
section
design
bioactiv
foldam
compar
systemat
b
replac
aabaaab
pattern
caus
minim
distort
ahelix
geometri
see
fig
sequestr
bresidu
one
face
helix
allow
key
aresidu
opposit
face
conserv
interact
although
less
matur
relat
approach
like
base
incorpor
gresidu
variou
type
also
worth
mention
number
agpeptid
scaffold
propens
adopt
helic
structur
report
bgpeptid
altern
band
gamino
acid
residu
also
special
interest
context
ahelix
mimicri
bgdipeptid
subunit
match
number
atom
atripeptid
segment
appropri
preorgan
residu
promot
format
helic
conform
strong
relationship
ahelix
interest
note
bg
peptid
segment
insert
long
ahel
segment
form
coil
coil
gellman
et
al
also
report
abg
heterogen
sequenc
agaaba
pattern
propens
form
stabl
helic
water
surprisingli
show
g
residu
display
actual
high
helic
propens
best
sequenc
ahelix
mimicri
combin
cyclic
bresidu
acycl
g
residu
releas
constraint
backbon
natur
reli
specif
stereochemistri
build
proteinogen
architectur
lconfigur
aamino
acid
use
protein
biosynthesi
occasion
diastereomer
protein
contain
discret
l
residu
replac
prepar
evalu
singl
damino
acid
insert
affect
local
global
fold
behavior
case
approach
led
increas
protein
stabil
although
homochir
polym
essenti
proper
fold
adopt
specif
function
shape
mix
land
dresidu
polypeptid
sequenc
use
expand
scope
access
fold
pattern
case
gramicidina
hydrophob
membran
activ
peptid
altern
l
sequenc
fold
mix
helix
also
name
bhelix
similar
bsheettyp
structur
pair
j
angl
lie
allow
bsheet
region
ramachandran
map
l
residu
bhelic
form
lpeptid
either
rightor
lefthand
depend
paramet
sequenc
length
environ
variou
period
henc
pore
size
predict
found
experiment
bhelic
gramicidina
also
exist
either
singl
helic
stabil
parallel
hbond
parallel
antiparallel
doubl
helic
proof
principl
toward
develop
ligand
biolog
target
kulp
clark
engin
hydrophil
lpeptid
sequenc
abl
fold
bhelix
polar
media
shown
upon
switch
solvent
aqueou
buffer
methanol
heterochir
peptid
fold
bhairpinlik
secondari
structur
bhelic
supersecondari
structur
dpeptid
natur
occur
natur
howev
repres
interest
class
peptidomimet
therapeut
applic
could
mimic
natur
bioactiv
peptid
resist
enzymat
degrad
less
immunogen
correspond
lenantiom
context
mirror
imag
phage
display
see
also
section
design
synthet
access
divers
enhanc
improv
biopolym
mimicri
ahelix
mimicri
modul
proteinprotein
interact
foldam
target
intracellular
ppi
remark
approach
identifi
damino
acid
peptid
dmini
protein
sequenc
specif
bind
select
protein
target
abiot
foldam
typic
contain
aromat
ring
backbon
distinguish
aliphat
backbon
protein
relat
biotic
foldam
although
fold
propens
aromat
oligom
reli
noncoval
interact
pp
stack
hbond
restrict
rotat
around
aromat
unit
strong
geometr
constraint
essenti
featur
make
secondari
structur
foldam
highli
stabl
predict
hamilton
cowork
origin
describ
oligoamid
aromat
foldam
obtain
combin
orthoaminobenzo
acid
ie
anthranil
acid
fig
acid
monom
fig
demonstr
correspond
heteropentam
adopt
helic
conform
similar
helicen
stabil
intramolecular
hbond
pattern
nearest
neighbor
group
structur
resembl
helic
report
lehn
oligobipyridin
undergo
spontan
selforgan
doublehel
structur
upon
metal
bind
sinc
earli
work
sever
oligoaryl
acid
oligom
fig
heteroarylamid
oligoquinolin
fig
describ
promot
helic
conform
well
oligoaromat
link
hydrazon
urea
moieti
curvatur
result
helic
modul
sever
factor
substitut
pattern
aromat
ring
ie
ortho
meta
para
introduct
hydrogenbond
donoracceptor
group
rigidifi
backbon
type
aromat
ring
benzen
pyridin
pyrimidin
naphthalen
handed
helix
also
promot
choic
stereocontrol
monom
lead
chiral
induct
make
aromat
foldam
water
solubl
biolog
activ
certainli
challeng
aliphat
counterpart
inher
hydrophob
chemic
diverg
biomacromolecul
synthet
challeng
nevertheless
number
exampl
literatur
linear
aromat
oligom
amphipath
charact
exhibit
potent
antimicrobi
activ
report
group
degrado
tew
huc
cowork
design
first
fulli
watersolubl
helic
quinolin
oligoamid
attach
sever
ammonium
side
chain
along
backbon
actual
demonstr
helix
conform
stabil
molecul
enhanc
polar
media
compar
organ
solvent
heterogen
backbon
also
explor
abiot
foldam
form
hybrid
scaffold
expect
display
uniqu
fold
behavior
due
absenc
common
featur
aliphat
aromat
build
block
number
aromat
unit
along
sequenc
properli
control
fold
properti
abiot
part
may
kept
benefit
wide
divers
side
chain
commerci
avail
amino
acid
watersolubl
aamino
acidquinolin
oligoamid
thu
design
order
form
linear
array
proteinogen
side
chain
one
face
helix
perform
synthesi
hybrid
sequenc
power
solidphas
synthesi
sp
strategi
develop
via
situ
format
amino
acid
chlorid
interact
specif
secondari
structur
element
protein
target
altern
structurebas
approach
develop
requir
knowledg
effect
function
group
arrang
surfac
protein
base
welldefin
preorgan
minimalist
scaffold
decor
sidechain
function
group
appropri
spatial
distribut
order
interact
favor
target
fig
particular
postul
linear
array
appropri
space
side
chain
nonhel
scaffold
effici
mimic
project
nativ
ahelix
residu
topograph
mimet
may
synthet
access
convent
helic
howev
practic
use
peptidomimet
framework
need
chemic
modular
allow
appendag
proteinogen
side
chain
high
rigid
scaffold
desir
perfect
overlap
critic
function
group
ahelix
achiev
otherwis
conform
flexibl
may
necessari
long
relev
conform
may
sampl
access
thermodynam
kinet
barrier
hamilton
group
design
first
true
ahelix
mimet
use
terphenyl
scaffold
report
structur
function
analog
defin
region
kinas
ahelix
key
side
chain
involv
biolog
interact
ppi
membran
disrupt
usual
locat
along
face
ahelix
residu
consid
term
function
orner
et
al
found
trissubstitut
terphenyl
deriv
stagger
conform
allow
right
arrang
substitu
project
critic
function
group
similar
place
ahelix
sever
potent
inhibitor
ppi
develop
function
terphenyl
terephthalamid
trispyridylamid
scaffold
later
design
benzoylurea
oligom
altern
oligophenylen
mimic
eight
turn
ahelix
solv
synthesi
well
water
solubl
issu
extend
scaffold
need
group
also
develop
effici
nonhel
mimet
biolog
activ
ahelic
base
aromat
backbon
oligobenzamid
pyridazin
pyridyl
piperidinepiperidinon
et
al
hand
report
oligooxopiperazin
scaffold
chiral
nonaromat
topograph
helix
mimet
shown
oligooxopiperazin
deriv
could
mimic
orient
three
critic
bind
residu
ahel
domain
interfac
hypoxiainduc
factor
cysteinehistidinerich
domain
see
section
interact
next
import
challeng
design
amphipath
ahelix
mimet
base
nonhel
scaffold
improv
affin
target
select
toward
goal
face
helix
consid
strategi
mimic
residu
one
face
residu
explor
comparison
helic
far
fewer
exampl
foldam
design
mimic
bsheettyp
secondari
structur
mainli
due
larg
surfac
interact
need
stabil
structur
also
fact
bsheet
structur
tend
aggreg
precipit
make
character
difficult
apeptid
bsheet
compos
extend
bstrand
region
align
later
interact
one
anoth
hydrogen
bond
bstrand
made
linear
array
aamino
acid
side
chain
point
altern
backbon
plane
bstrand
align
direct
form
parallel
bsheet
stabil
hydrogenbond
ring
convers
antiparallel
bsheet
hydrogenbond
ring
obtain
bstrand
align
opposit
direct
bsheet
protein
flat
rather
twist
righthand
fashion
also
tend
selfassembl
hydrophob
interact
secondari
structur
element
creat
compact
tertiari
quaternari
structur
earli
exampl
de
novo
design
foldam
sheetlik
hairpintyp
structur
organ
solvent
report
bpeptid
gpeptid
group
gellman
seebach
design
band
gpeptid
propos
structur
studi
aqueou
environ
topdown
approach
wherebi
aresidu
structur
apeptid
bsheet
replac
b
g
residu
counterpart
explor
start
prototyp
watersolubl
hairpin
sequenc
horn
cowork
shown
mix
abpeptid
eg
contain
singl
b
mutat
crossstrand
posit
adopt
twostrand
hairpin
fold
aqueou
solut
fig
main
difficulti
design
heterogen
abpeptid
sheettyp
structur
resid
differ
direction
interstrand
hydrogenbond
pattern
impos
bresidu
well
alter
display
side
chain
rel
natur
apeptid
later
horn
group
shown
altern
bresidu
replac
strategi
aa
b
aa
bb
could
use
maintain
fold
pattern
sidechain
display
origin
apeptid
hairpin
associ
energet
penalti
result
addit
backbon
conform
freedom
martinek
et
al
first
report
effect
systemat
ato
b
substitut
multipl
strand
watersolubl
bioactiv
bsheet
eg
fig
show
higher
detriment
effect
fold
substitut
occur
hydrophob
core
region
mainli
due
geometr
constraint
prevent
good
pack
rather
destabil
hydrogenbond
network
although
foldam
display
decreas
fold
propens
compar
natur
counterpart
could
still
exhibit
interest
biolog
properti
altern
introduct
constrain
gamino
acid
residu
eg
maminobenzo
acid
acid
strand
proteinderiv
hairpin
found
effect
approach
stabil
nativelik
hairpin
fold
aqueou
solut
maintain
origin
display
natur
side
chain
success
design
conform
stabl
watersolubl
bstrand
bsheet
peptidomimet
may
also
integr
addit
element
promot
bsheet
secondari
structur
includ
nonnatur
turn
segment
preorgan
hbond
templat
eg
hao
unit
invent
nowick
macrocycl
combin
thereof
fig
altern
approach
includ
base
short
topograph
mimet
extend
peptid
structur
oligopyrrolinon
develop
group
smith
hirschmann
fig
pyrrolinonepyrrolidin
oligom
invent
burgess
cowork
fig
fig
hydantoin
oligom
fig
aryl
imidazolidinon
develop
hamilton
group
fig
minimalist
mimet
shown
interest
nonpeptid
molecular
scaffold
mimic
desir
sidechain
function
bstrand
watersolubl
exampl
function
studi
aqueou
media
still
lack
natur
numer
recognit
event
trigger
conform
switch
time
revers
allow
altern
state
respons
extern
stimulu
base
principl
chemist
sought
design
molecul
abl
predict
chang
conform
specif
condit
stimuli
variou
sourc
light
excit
redox
process
proton
state
ion
bind
interact
biopolym
field
foldam
sever
class
oligomer
backbon
show
strong
conform
prefer
stand
alon
solut
fold
welldefin
secondari
structur
upon
bind
complementari
target
mani
abiot
system
report
fold
guest
recognit
eg
ion
coupl
process
mainli
organ
solvent
case
biolog
relev
synthet
oligom
express
similar
properti
aqueou
environ
fold
induc
recognit
biolog
target
pyrroleimidazol
pyim
oligom
develop
dervan
cowork
import
class
dnabind
polyamid
whose
design
base
natur
product
distamycin
oligom
adopt
hairpinshap
structur
bound
minor
groov
dna
sequenc
encod
antiparallel
sidebysid
pair
heterocycl
amino
acid
distinguish
edg
four
watsoncrick
base
pair
accord
follow
pair
rule
im
nmethylimidazol
py
nmethylpyrrol
code
gc
base
pair
pyim
code
cg
hp
hydroxypyrrol
py
code
ta
pyhp
code
pypi
recogn
ta
base
pair
past
decad
extens
studi
conduct
turn
segment
monom
backbon
improv
recognit
properti
specif
target
dna
bind
affin
exampl
introduct
flexibl
balanin
residu
aromat
backbon
found
improv
bind
polyamid
long
bind
site
allevi
curvatur
mismatch
wherea
chiral
substitut
gaminobutyr
acid
turn
motif
enhanc
properti
polyamid
hairpin
term
specif
bind
orient
prefer
optim
oligoamid
bind
dna
sequencespecif
manner
affin
rang
transcript
factor
display
interest
biolog
activ
see
section
nucleic
acid
recognit
pharmacokinet
tissu
distribut
oligoamid
also
select
distinguish
dna
correspond
rna
sequenc
mainli
due
decreas
polyamiderna
shape
complementar
reduc
solvat
wide
shallow
doublestrand
rna
minor
groov
make
use
probe
dnamedi
process
peptid
nucleic
acid
pna
develop
nielsen
cowork
anoth
famili
oligom
fold
upon
hybrid
dna
mix
oligom
display
pseudopeptid
backbon
compos
n
glycin
unit
bear
g
c
nucleobas
side
chain
attach
via
methylen
carbonyl
spacer
pna
shown
form
stabl
hybrid
complex
base
watsoncrick
base
pair
either
dna
rna
stabl
cognat
nucleic
acidnucl
acid
duplex
bind
event
occur
strand
invas
pna
oligom
displac
strand
oligonucleotid
duplex
crystal
structur
palindrom
sixbas
pair
pna
duplex
obtain
well
pna
complex
form
homoduplex
triplex
motif
latter
structur
illustr
conform
flexibl
high
structur
adapt
pna
backbon
abil
singl
pna
strand
adopt
extend
helic
conform
allow
nucleobas
stack
complex
hydrogenbond
network
format
chiral
gpnadna
duplex
also
character
lead
righthand
helic
pform
gsubstitut
pna
alreadi
preorgan
characterist
helic
structur
even
absenc
hybrid
show
thu
stronger
helix
propens
due
presenc
substitu
gposit
strongli
preorgan
backbon
helix
propag
cto
nterminu
cooper
fashion
pna
foldam
good
candid
antisens
gene
therapi
well
applic
molecular
biolog
diagnost
poor
solubl
physiolog
condit
still
prevent
develop
pnabas
therapeut
number
foldam
backbon
known
adopt
welldefin
conform
organ
solvent
necessarili
fold
singl
wellcharacter
structur
aqueou
environ
case
b
pentadecapeptid
report
seebach
cowork
bind
dna
duplex
fig
design
assum
helic
conform
distribut
posit
charg
side
chain
ie
b
ly
could
mediat
ionic
interact
phosphat
group
oligonucleotid
backbon
nonspecif
manner
b
asn
residu
could
make
specif
hbond
interact
dna
major
groov
recognit
face
helix
aqueou
environ
b
pentadecapeptid
exhibit
typic
cd
signatur
would
indic
helic
fold
howev
presenc
dna
duplex
characterist
cd
signal
helix
observ
support
stabil
helic
conform
upon
dna
bind
group
also
report
hairpintyp
arrang
secondari
structur
bpeptid
could
also
initi
andor
enforc
chelat
zn
cation
cy
side
chain
introduc
appropri
posit
similar
found
zn
finger
domain
generegulatori
protein
altogeth
specif
exampl
studi
conduct
type
backbon
eg
peptoid
aromaticaliphat
oligoamid
multipl
conform
might
coexist
support
idea
synthet
oligom
conform
variabl
necessarili
less
import
congen
adopt
stabl
defin
structur
also
potenti
applic
larg
fraction
foldam
backbon
describ
previou
section
intend
mimic
individu
protein
secondari
structur
element
ahelic
bsheettyp
architectur
foldam
ahelix
mimet
particular
found
widespread
use
scaffold
target
ppi
see
section
ahelix
mimicri
modul
proteinprotein
interact
wherea
protein
interfac
rel
simpl
accommod
individu
ahelic
key
recognit
element
other
much
complex
broader
less
defin
suggest
potenti
larger
foldam
architectur
compris
two
secondari
structur
element
arrang
space
de
novo
design
complex
unimolecular
fold
supersecondari
tertiari
structur
well
noncoval
assembl
quaternari
structur
construct
foldam
backbon
high
level
control
final
structur
howev
much
challeng
due
part
difficulti
chemic
synthes
long
oligomer
sequenc
requir
creat
tertiari
structur
ii
necess
implement
still
poorli
understood
design
principl
bring
secondari
element
togeth
iii
need
character
assembl
high
resolut
test
hypothes
helixturnhelix
hth
helic
hairpin
motif
obtain
two
antiparallel
ahelic
connect
short
turnloop
segment
typic
residu
probabl
simpl
design
beyond
individu
helic
appear
privileg
scaffold
target
larg
protein
interfac
principl
govern
helic
hairpin
format
protein
analyz
detail
strategi
stabil
structur
emerg
recent
year
sever
attempt
construct
foldamerbas
hth
motif
supersecondari
structur
studi
conduct
aqueou
solut
two
bpeptid
helic
hairpin
util
dprogli
cystin
unit
interhel
segment
character
solut
helic
aromat
oligoamid
rigid
diamin
interhelix
connector
also
employ
abpeptid
helixloophelix
tertiari
structur
wherebi
aresidu
regular
interv
replac
b
analog
bear
side
chain
sequenc
biolog
relev
apeptid
develop
target
specif
protein
surfac
progress
made
toward
creation
even
complex
fulli
artifici
tertiari
structur
combin
multipl
secondari
structur
element
structur
character
atom
resolut
exampl
includ
compact
multihel
structur
multistrand
artifici
bsheet
peptoid
bpeptid
aromat
oligoamid
backbon
mirror
imag
phage
display
also
appli
select
fulli
artifici
proteaseresist
mini
dprotein
scaffold
target
specif
protein
surfac
pdb
id
http
fig
section
target
vascular
endotheli
growth
factor
signal
anoth
promis
approach
involv
redesign
biopolym
mix
natur
nonnatur
backbon
singl
chain
eg
protein
prosthesi
composit
foldam
protein
obtain
replac
subset
aresidu
unnatur
build
block
sequenc
parent
protein
swap
entir
protein
secondari
structur
element
ahelic
foldam
counterpart
protein
backbon
engin
benefit
current
advanc
total
protein
chemic
synthesi
semisynthesi
use
interrog
protein
fold
address
role
individu
fold
segment
modifi
physicochem
properti
replic
modul
protein
function
noteworthi
exampl
variant
semisynthet
protein
ctermin
ahelix
replac
design
sequenc
b
residu
shown
display
activ
compar
nativ
howev
highresolut
structur
inform
structur
activ
relationship
studi
report
studi
complementari
work
gellman
horn
group
provid
detail
atom
precis
impact
bresidu
substitut
helic
segment
within
discret
tertiari
structur
eg
villin
headpiec
subdomain
domain
protein
g
streptococcu
bacteria
quaternari
structur
eg
yeast
transcript
activ
peptid
particular
horn
group
shown
tertiari
fold
accommod
unnatur
backbon
content
combin
damino
acid
aib
nmeamino
acid
b
amino
acid
replac
differ
secondari
structur
element
helix
loop
sheet
turn
highlight
remark
plastic
protein
backbon
eg
pdb
id
fig
compar
analysi
fold
structur
thermodynam
deriv
accord
residu
type
ahel
secondari
structur
show
sever
trend
b
b
residu
similar
helix
fold
propens
side
chain
involv
key
interact
ii
constrain
cyclic
bresidu
gener
lead
modest
increas
fold
stabil
compar
acycl
bresidu
iii
aib
residu
chiral
counterpart
prove
better
bresidu
stabil
tertiari
fold
effort
assembl
foldam
quaternari
structur
also
promis
direct
creat
increasingli
divers
foldam
higher
order
structur
includ
singlestrand
tertiari
fold
coval
linkag
differ
element
macrocycl
bsheet
peptid
mimic
see
fig
report
selfassembl
atom
precis
nanos
structur
fibrillik
annular
porelik
assembl
foldam
helix
bundl
variou
stoichiometri
character
crystal
state
includ
b
peptid
octamer
helix
bundl
eg
fig
tetramer
bundl
form
bpeptid
hybrid
helic
sixhelix
bundl
form
n
n
link
oligourea
proteinogen
side
chain
eg
fig
altern
topolog
superhel
channel
tunabl
diamet
also
form
vari
proport
distribut
hydrophil
hydrophob
side
chain
helix
surfac
assembl
eg
b
peptid
octamer
helix
bundl
demonstr
use
molecular
recognit
properti
includ
abil
bind
differenti
biomolecul
sugar
aqueou
solut
remark
progress
accomplish
past
year
discoveri
mani
potent
bioactiv
foldam
origin
divers
backbon
target
whole
spectrum
bio
macro
molecul
membran
protein
surfac
nucleic
acid
secondari
structur
predict
sequenc
programm
modular
well
compat
sp
method
major
determin
success
structur
data
high
resolut
structureguid
design
also
becom
increasingli
import
project
aim
design
potent
inhibitor
ppi
design
synthet
access
divers
enhanc
improv
biopolym
mimicri
develop
particular
foldam
scaffold
discuss
previou
section
medicin
chemistri
applic
transform
enabl
platform
still
requir
multipl
challeng
met
current
one
challeng
task
resid
reproduc
spatial
arrang
key
side
chain
found
surfac
cognat
biopolym
epitop
mimic
synthet
access
modular
chemistri
thu
highli
need
introduc
multipl
level
divers
divers
side
chain
substitut
pattern
backbon
isoster
modif
rapidli
access
larg
seri
compound
screen
target
interest
compar
parent
aamino
acid
band
gamino
acid
monomer
unit
character
much
greater
chemic
divers
conform
versatil
exampl
bamino
acid
unit
five
substitut
posit
compar
three
acounterpart
number
configur
isom
increas
eight
vs
two
aamino
acid
access
divers
often
need
exert
control
fold
sidechain
display
fine
tune
improv
interact
term
affin
andor
specif
given
foldam
target
surfac
eg
combin
b
amino
acid
cyclic
bamino
acid
residu
design
effect
ahelix
mimic
abpeptid
studi
aim
delin
rule
govern
fold
constitu
unit
new
substitut
pattern
character
structur
result
oligom
atom
resolut
conduct
systemat
mani
differ
system
eg
gamino
acid
oligourea
monomer
unit
exampl
shift
side
chain
one
carbon
monom
constitu
oligourea
may
use
subtli
vari
rel
distribut
side
chain
surfac
peptidomimet
possibl
optim
bind
given
protein
surfac
effort
toward
expans
monom
librari
limit
aliphat
unit
context
abiot
aromat
oligoamid
exampl
complet
array
suitabl
design
monom
vari
size
shape
employ
produc
foldam
receptor
high
select
specif
monosaccharid
eg
fructos
mix
natur
nonpeptid
backbon
modul
conform
function
behavior
natur
biopolym
anoth
promis
approach
lead
function
mimic
bioactiv
apeptid
sequenc
eg
abpeptid
hybrid
ahelix
mimet
practic
impact
medicin
chemistri
program
develop
use
monom
librari
must
coupl
effici
rapid
oligom
synthesi
scheme
peptid
backbonemodif
strategi
base
bamino
acid
residu
replac
readili
implement
necessari
abpeptid
access
via
effect
sp
procedur
mani
protect
bamino
acid
report
commerci
avail
hold
true
peptoid
synthet
methodolog
solid
support
appropri
sub
monomer
precursor
extrem
well
establish
effici
sp
methodolog
develop
grow
number
less
convent
foldam
backbon
aliphat
oligourea
oligom
carboxyl
acid
hybrid
aamino
acidquinolin
oligoamid
nalkyl
aromat
oligobenzamid
ahelix
mimet
pyim
polyamid
mani
case
microwav
assist
employ
overcom
synthet
difficulti
inher
backbon
eg
poor
nucleophil
aromat
amin
simpli
acceler
product
longer
foldam
sequenc
case
optim
sp
procedur
exploit
prepar
larg
foldam
librari
highthroughput
screen
gellman
cowork
use
polystyren
macrobead
microwav
irradi
gener
mediums
onebeadonestock
solut
combinatori
librari
via
splitandmix
approach
screen
librari
inhibitor
interact
howev
permit
identif
compound
significantli
potent
previous
report
bpeptid
sequenc
presum
limit
size
librari
similarli
highqual
onebeadonebpeptid
librari
suitabl
onbead
screen
report
schepartz
use
identifi
inhibitor
interact
ic
valu
low
mm
rang
follow
simpl
tandem
mass
spectrometri
msm
decod
method
complementari
chemic
method
gener
nonnatur
oligom
correspond
librari
sever
biotechnolog
approach
gain
increas
attent
context
nonnatur
oligom
foldam
mirror
imag
phage
display
power
eleg
techniqu
identifi
dpeptid
ligand
specif
protein
target
howev
mirror
imag
phage
display
requir
mirror
imag
target
chemic
synthes
current
limit
rel
small
protein
target
excit
new
approach
farreach
develop
applic
potenti
current
explor
exploit
biosynthet
machineri
respons
protein
synthesi
incorpor
noncanon
backbonemodifi
residu
one
sever
desir
posit
peptid
chain
spectacular
progress
made
direct
use
vitroreconstitut
translat
system
produc
short
polypeptid
contain
divers
exot
unit
damino
acid
nmethylamino
acid
bhydroxi
acid
suga
cowork
use
genet
code
expans
reprogram
methodolog
incorpor
singl
multipl
b
amino
acid
peptid
chain
shown
bamino
acid
compat
ribosom
translat
b
gli
lb
ala
lb
gln
land
db
phg
lb
met
show
highest
incorpor
doubleincorpor
experi
use
bamino
acid
reveal
elong
peptid
success
bamino
acid
prohibit
doubl
incorpor
bamino
acid
residu
possibl
aresidu
insert
year
schepartz
report
b
phe
residu
incorpor
fulllength
protein
vivo
use
escherichia
coli
strain
express
mutant
ribosom
one
inher
limit
use
isol
lapeptid
therapeut
suscept
degrad
circul
enzym
consider
shorten
biolog
lifetim
durat
action
vivo
contrast
foldam
built
nonaamino
acid
unit
strong
potenti
resist
enzymat
degrad
increas
number
biotic
abiot
backbon
test
display
remark
vitro
stabil
varieti
peptidas
bacteri
fungal
eukaryot
origin
eg
leucyl
aminopeptidas
proteinas
k
trypsin
chymotrypsin
elastas
amidas
blactamas
proteasom
pepsin
subtilisin
cathepsin
thermolysin
case
band
gpeptid
well
apeptoid
bpeptoid
n
n
link
oligourea
aromat
oligoamid
dpeptid
sulfonogaapeptid
howev
experi
conduct
class
enzym
involv
drug
metabol
cytochrom
enzym
situat
complex
hybrid
foldam
combin
unnatur
monomer
unit
proteinogen
aamino
acid
interest
hybrid
foldam
stem
increas
chemic
structur
divers
brought
combin
differ
type
monomer
unit
possibl
backbon
close
mimic
target
proteinbind
surfac
well
document
insert
singl
noncanon
unit
bamino
acid
residu
peptid
bond
isoster
scissil
bond
also
increas
stabil
proxim
modifi
residu
earli
model
studi
seebach
cowork
bpeptid
contain
ntermin
intern
bamino
acid
residu
shown
stabil
hybrid
abpeptid
degrad
pronas
mixtur
nonspecif
endoand
exopeptidas
highli
depend
locat
aresidu
sequenc
aamino
acid
locat
nterminu
bpeptid
cleavag
aa
abpeptid
bond
depend
aresidu
pronas
observ
howev
natur
aamino
acid
embed
bpeptid
sequenc
pattern
nterminu
cap
hydrolysi
detect
proteolyt
stabil
cours
expect
increas
densiti
unnatur
unit
sequenc
better
understand
extent
insert
noncanon
residu
eg
damino
acid
nmethyl
amino
acid
b
amino
acid
tetrasubstitut
amino
acid
protect
adjac
posit
gain
compar
view
differ
type
noncanon
unit
horn
cowork
systemat
studi
effect
resist
chymotrypsin
singl
tandem
aamino
acid
replac
vari
natur
posit
within
model
peptid
sequenc
contain
chymotrypsinspecif
cleavag
site
specif
sequenc
found
invers
stereogen
center
daresidu
replac
ca
tetrasubstitut
aibtyp
residu
replac
effect
modif
protect
degrad
wherea
nmearesidu
least
effect
replac
intermedi
level
protect
degrad
observ
peptid
contain
b
replac
extend
studi
tandem
mutant
differ
space
horn
cowork
found
combin
replac
synergist
correl
densiti
unnatur
unit
proteolyt
stabil
necessarili
simpl
pioneer
work
ahelix
mimicri
ab
peptid
gellman
cowork
demonstr
evenli
space
b
replac
along
bioactiv
apeptid
sequenc
certainli
repres
effici
way
achiev
maxim
protect
keep
chemic
alter
start
peptid
sequenc
minimum
exampl
ahelix
mimet
aabaaab
aaab
pattern
describ
section
heterogen
backbon
peptidefoldam
chimera
see
also
section
ahelix
mimicri
modul
proteinprotein
interact
ligand
gproteincoupl
receptor
hormon
like
analog
significantli
resist
often
fold
presenc
proteinas
k
origin
bioactiv
apeptid
intend
mimic
result
wilson
laboratori
suggest
gener
approach
lead
reduc
suscept
proteas
extend
hybrid
backbon
contain
type
unnatur
unit
aromat
unit
grow
interest
develop
cation
membraneact
antimicrobi
peptid
amp
altern
convent
antibiot
treatment
bacteri
infect
endogen
amp
essenti
compon
innat
immun
system
eukaryot
organ
plant
mammal
serv
first
line
defens
broad
rang
microorgan
includ
gramneg
gramposit
bacteria
amp
form
larg
highli
divers
famili
molecul
rang
size
amino
acid
residu
share
common
physicochem
featur
though
amp
larg
cation
display
amphiphil
charact
thu
allow
interact
preferenti
neg
charg
bacteri
membran
number
issu
suscept
proteolyt
degrad
toxic
follow
system
applic
need
address
amp
meet
full
potenti
clinic
addit
increas
evid
pathogen
bacteria
develop
resist
endogen
amp
varieti
mechan
often
involv
biophys
biochem
chang
bacteri
cell
wall
one
approach
circumv
limit
involv
design
synthet
analog
recapitul
amphiphil
charact
amp
membraneact
foldam
link
structur
function
foldam
gener
facilit
dual
control
monom
sequenc
secondari
structur
well
divers
build
block
repertoir
larg
fraction
foldam
amp
mimic
report
design
form
global
amphiphil
helic
cluster
hydrophob
cation
residu
surfac
helix
fig
case
antimicrobi
base
bpeptid
peptoid
n
n
link
aliphat
oligourea
oligo
ureaamid
hybrid
recent
sulfonogaapeptid
helic
scaffold
three
residu
per
helix
turn
b
peptid
peptoid
antimicrobi
sequenc
report
base
short
triad
repeat
hydrophobichydrophobiccation
residu
helic
structur
residu
per
turn
ie
bpeptid
n
n
link
oligourea
cation
residu
arrang
creat
polar
surfac
cover
twofifth
threefifth
helix
circumfer
design
principl
led
potent
molecul
broadspectrum
activ
rang
multidrugresist
gramposit
gramneg
bacteri
pathogen
includ
clinic
relev
strain
among
e
coli
staphylococcu
aureu
pseudomona
aeruginosa
frequent
test
report
activ
potent
deriv
minimum
inhibitori
constant
mic
rang
mgml
compar
favor
known
peptid
melittin
honeybe
toxin
pexiganan
potent
synthet
analog
natur
magainin
omiganan
peptid
current
clinic
dermatolog
applic
interestingli
cation
foldam
mimic
amp
peptoid
oligourea
backbon
shown
equal
activ
gramposit
infecti
bacteria
mycobacterium
tuberculosi
bacillu
anthraci
caus
agent
anthrax
respect
systemat
structureact
relationship
studi
conduct
improv
potenc
importantli
reduc
hemolyt
activ
increas
select
compound
bacteri
membran
repres
exampl
seri
includ
helic
bnonapeptid
contain
transachc
residu
b
hli
residu
eg
peptoid
dodecam
contain
achir
monom
sulfonogaapeptid
bpeptid
compos
hydrophob
acpc
residu
cation
aminopyrrolidin
carboxyl
acid
apc
residu
helic
oligourea
eg
surprisingli
isoster
g
peptid
analog
eg
despit
close
structur
similar
similar
sidechain
distribut
found
display
margin
antibacteri
activ
origin
differ
oligourea
g
peptid
yet
fulli
understood
could
relat
subtl
differ
polar
geometri
two
helic
backbon
altern
recent
shown
aliphat
oligourea
ideal
preorgan
interact
anion
guest
sitespecif
manner
posit
end
helix
dipol
properti
may
suggest
complementari
mechan
account
interact
properti
antimicrobi
oligourea
helic
model
phospholipid
membran
well
bacteri
membran
case
unexpect
complex
relationship
structur
function
design
antibacteri
foldam
particularli
among
bpeptid
sequenc
design
adopt
global
amphiphil
helic
structur
led
moder
activ
compound
contrast
control
scrambl
sequenc
concurr
fold
backbon
even
far
remot
natur
peptid
arylamid
arylurea
foldam
explor
membraneact
antibacteri
agent
begin
polym
compris
altern
isophthal
acid
unit
group
tew
degrado
develop
success
program
led
discoveri
potent
antimicrobi
remark
activ
safeti
profil
oligom
molecular
weight
rang
da
adopt
facial
amphiphil
structur
cation
hydrophob
side
chain
distribut
opposit
face
molecul
fig
conform
molecul
control
format
intramolecular
hydrogen
bond
thioether
group
instal
isophthal
unit
nh
phenylen
diamin
unit
firstgener
oligom
exemplifi
shown
exhibit
modest
activ
aureu
e
coli
replac
isophthal
unit
pyrimidin
unit
acid
unit
use
reinforc
hbond
network
stabil
planar
conform
molecul
addit
rigidif
backbon
accompani
signific
gain
activ
gramposit
gramneg
bacteria
shown
mic
mm
aureu
e
coli
hc
mm
hc
concentr
caus
lysi
human
red
blood
cell
facial
amphiphil
urealink
aryl
oligom
eg
found
equal
potent
exhibit
signific
hemolyt
activ
hc
near
mic
introduct
termin
guanidinium
group
replac
tertbutyl
group
trifluoromethyl
group
led
improv
potenc
molecul
exhibit
low
mic
varieti
gramposit
gramneg
human
clinic
isol
minim
toxic
mammalian
cell
detail
biophys
studi
suggest
molecul
like
destabil
anion
lipid
membran
primarili
alter
membran
electr
potenti
creation
transient
defect
membran
less
disrupt
manner
typic
amp
despit
fact
foldam
backbon
antibacteri
activ
report
resist
proteolyt
degrad
cognat
apeptid
rel
report
describ
activ
anim
model
vivo
studi
includ
evalu
arylamid
foldam
aureu
thigh
infect
model
n
n
link
oligourea
inhal
cutan
mous
model
b
anthraci
infect
discuss
section
vivo
studi
bioactiv
foldam
ppi
mediat
numer
biolog
process
function
live
organ
thu
repres
promis
new
target
develop
new
therapeut
although
field
ppi
inhibitorsmodul
wit
spectacular
progress
past
two
decad
develop
variou
approach
base
small
molecul
recombin
protein
design
synthet
molecul
aim
interf
ppi
remain
except
challeng
part
proteinprotein
interfac
except
divers
term
size
shape
mediums
molecul
apeptid
use
mimic
secondari
structur
element
larger
proteinprotein
interfac
socal
secondarystructur
epitop
thu
may
contribut
fill
gap
small
molecul
biolog
develop
novel
class
ppi
modul
interest
peptid
also
stem
grow
contribut
worldwid
pharmaceut
market
wit
number
peptid
therapeut
clinic
trial
unpreced
number
market
approv
howev
alreadi
discuss
isol
linear
peptid
gener
limit
poorli
defin
conform
ii
suscept
degrad
circul
enzym
iii
except
lack
cell
permeabl
possibl
limit
use
extracellular
target
context
chemic
approach
aim
reinforc
mimick
protein
secondari
structur
element
develop
innov
ppi
modul
flourish
ahelic
frequent
found
recognit
element
protein
perhap
amen
chemic
modif
much
effort
devot
stabil
mimicri
popular
approach
develop
specif
increas
helic
content
short
apeptid
includ
limit
introduct
constrain
adisubstitut
amino
acid
ii
sidechaintosidechain
macrocycl
iii
introduct
ntermin
templat
coval
hydrogenbond
surrog
method
appli
success
creat
effect
modul
ahelixmedi
ppi
note
peptidebas
inhibitor
exhibit
improv
properti
cell
permeabl
expand
rang
target
current
consid
suitabl
drug
develop
complementari
approach
ahelix
mimicri
ppi
modul
base
foldam
emerg
last
year
alreadi
show
great
promis
essenti
two
strategi
develop
parallel
first
one
featur
helic
guid
principl
focus
artifici
backbon
predict
helic
pattern
high
degre
similar
apeptid
wherea
second
one
minimalist
focus
side
chain
display
rigid
extend
backbon
topograph
mimic
quit
remot
natur
peptid
today
signific
progress
ahelix
mimicri
inhibit
ppi
accomplish
differ
class
artifici
backbon
includ
bpeptid
eg
bpeptid
mimet
heterogen
oligoamid
contain
variou
combin
aand
bamino
acid
residu
eg
mix
aabaaab
aaab
peptid
recapitul
bind
surfac
known
apeptid
inhibitor
target
bclx
l
protein
respect
extend
scaffold
eg
terphenyl
aromat
oligoamid
oligopyridin
oligooxopiperazin
deriv
inhibitor
bclx
l
protein
mimet
envelop
virus
like
influenza
respiratori
syncyti
viru
rsv
sever
acut
respiratori
syndrom
sar
middl
east
respiratori
syndrom
mer
coronavirus
ebola
virus
share
common
fusion
mechan
mediat
viral
membran
fusion
glycoprotein
high
helic
content
fusion
process
lead
infect
cell
involv
major
refold
glycoprotein
format
socal
trimer
hairpin
ie
antiparallel
trimer
dimer
sixhelix
bundl
follow
bind
cellular
receptor
glycoprotein
undergo
conform
chang
lead
exposur
first
heptad
repeat
domain
insert
fusion
peptid
cellular
membran
subsequ
anoth
major
conform
chang
second
heptad
repeat
domain
fold
back
onto
form
stabil
sixhelix
bundl
structur
trimer
dimer
juxtapos
viru
cell
membran
membran
fusion
success
develop
enfuvirtid
fuzeon
peptid
target
transient
expos
domain
treatment
infect
establish
therapeut
valu
peptidebas
approach
aim
inhibit
assembl
sixhelix
bundl
noteworthi
strategi
sinc
adapt
envelop
virus
sar
mer
coronavirus
ebola
viru
measl
rsv
lead
discoveri
potent
viral
fusion
inhibitor
drawback
associ
use
natur
peptid
sequenc
includ
rapid
vivo
proteolysi
enfuvirtid
rel
short
halflif
plasma
drug
resist
crossreact
preexist
antibodi
patient
variou
chemic
approach
macrocycl
ie
lactam
hydrocarbon
stapl
backbon
modif
explor
increas
resist
proteolysi
peptid
fusion
inhibitor
success
mimicri
helic
peptid
inhibit
postfus
sixhelix
bundl
structur
format
achiev
period
replac
aamino
acid
proteaseresist
bamino
acid
sequenc
fig
pdb
id
optim
analog
sever
abpeptid
analog
aabaaab
pattern
design
introduc
bresidu
posit
involv
contact
trimer
surfac
peptid
differ
natur
bresidu
either
acycl
b
substitut
ringconstrain
acpc
apc
competit
fluoresc
polar
assay
measur
displac
fluoresc
label
chrpeptid
engin
fivehelix
bundl
protein
compound
constrain
acpc
b
residu
backbon
found
much
effect
k
nm
contain
exclus
acycl
b
residu
replac
k
nm
suggest
helix
preorgan
requir
remark
compound
found
equipot
parent
apeptid
cellcel
fusion
inhibit
assay
ic
nm
inhibit
infect
strain
ic
nm
display
improv
proteolyt
stabil
proteinas
k
assay
crystal
structur
abpeptid
complex
peptid
resolut
pdb
id
confirm
format
expect
sixhelix
bundl
orient
bamino
acid
residu
toward
solvent
predict
fig
introduct
b
glub
arg
pair
space
within
abpeptid
helix
see
compound
subsequ
found
equal
suitabl
ringconstrain
bresidu
enhanc
helic
propens
bind
trimer
inhibit
hiv
infect
cellbas
assay
howev
stabil
proteolysi
significantli
enhanc
compar
cognat
peptid
despit
fact
site
cleav
proteinas
k
one
suppress
substitut
three
ringconstrain
acpc
residu
b
residu
near
remain
proteinas
k
cleavag
site
ie
result
dramat
ie
improv
halflif
well
increas
bind
trimer
main
advantag
approach
convers
given
ahel
peptid
correspond
analog
improv
properti
rel
direct
like
gener
vide
infra
yet
number
posit
space
aabaaab
natur
b
vs
cyclic
bamino
acid
replac
certainli
need
finetun
optim
bioactiv
sever
foldamerbas
strategi
aim
discov
viral
fusion
inhibitor
describ
worth
mention
although
inhibitor
report
yet
potent
cite
earlier
studi
includ
identif
dpeptid
inhibitor
ebola
viru
use
mirror
imag
phage
display
techniqu
c
ii
de
novo
design
b
peptid
analog
hydrophob
pocketbind
domain
iii
use
terphenyl
scaffold
bear
hydrophob
side
chain
intend
mimic
hydrophob
repeat
peptid
abil
foldam
mimic
ahelic
interact
protein
surfac
high
specif
assess
sever
therapeut
import
ppi
link
cancer
includ
hypoxiainduc
factor
involv
antiapoptot
proapoptot
protein
famili
wherea
studi
concentr
singlehelix
mimet
recent
develop
explor
complex
foldam
architectur
supersecondari
tertiari
structur
target
broader
protein
surfac
cellular
uptak
engag
target
insid
cell
addit
key
issu
address
case
need
solv
possibl
applic
molecul
cellular
context
target
mention
section
intracellular
famili
complex
network
mutual
interact
structur
relat
protein
regul
fate
cell
activ
inhibit
apoptosi
prosurviv
member
bclx
l
bclw
display
three
four
conserv
homolog
domain
inhibit
apoptosi
sequest
ahel
death
induc
domain
proapoptot
famili
member
bax
bak
hydrophob
cleft
delin
domain
protein
bid
bim
bad
noxa
puma
bik
contain
one
domain
exert
proapoptot
effect
either
indirectli
bind
prosurviv
protein
prevent
bax
bak
sequest
directli
bind
activ
bax
bak
caus
mitochondri
outer
membran
permeabil
prosurviv
protein
overexpress
sever
type
cancer
thu
promot
surviv
malign
cell
select
inhibit
repres
promis
approach
induct
apoptosi
tumor
cell
sever
mimet
current
clinic
trial
stage
structur
atom
resolut
prosurviv
protein
bclx
l
complex
ahel
peptid
reveal
extens
contact
stripe
four
hydrophob
residu
ahelix
hydrophob
cleft
surfac
proteinbind
partner
well
signific
contribut
polar
interact
salt
bridg
asp
side
chain
project
anoth
side
helix
conserv
arg
residu
cleft
variou
foldamerbas
strategi
mimic
ahelic
possibl
target
prosurviv
member
report
main
challeng
resid
length
bioactiv
helix
mimic
key
hydrophob
residu
distribut
four
consecut
helix
turn
need
mimic
residu
two
face
ahelix
hydrophob
residu
one
face
polar
side
chain
anoth
face
earli
effort
gellman
group
reproduc
helic
display
side
chain
helic
abpeptid
result
weak
bclx
l
binder
illustr
gener
difficulti
identifi
appropri
scaffold
faith
ahelix
mimicri
reduc
foldam
segment
part
helix
gener
chimer
ab
peptid
led
signific
improv
ab
peptid
combin
ntermin
segment
made
altern
aand
cyclic
bamino
acid
acpc
apc
residu
ctermin
apeptid
segment
residu
bak
exhibit
tight
bind
bclx
l
k
nm
crystal
structur
complex
bclx
l
pdb
id
reveal
foldam
retain
gener
orient
natur
domain
abseg
form
structur
cyclic
bamino
acid
acpc
residu
make
contact
protein
surfac
fig
gener
approach
ahelix
mimicri
wherebi
smaller
proport
regularli
space
aresidu
distribut
target
peptid
sequenc
replac
correspond
homolog
bamino
acid
gener
follow
regular
aab
aaab
aabaaab
pattern
fig
explor
intens
gellman
group
context
domain
puma
bim
mimet
aabaaab
aaab
pattern
found
support
effect
ahelix
mimicri
identif
potent
bimderiv
abpeptid
like
aabaaab
pattern
aaab
pattern
larg
retain
bind
profil
nativ
bim
peptid
crystal
structur
complex
bclx
l
pdb
id
http
http
respect
confirm
two
abpeptid
close
mimic
natur
bim
domain
although
significantli
differ
distribut
bresidu
fig
bresidu
align
along
one
side
helix
direct
toward
solvent
four
key
hydrophob
side
chain
contribut
aresidu
contrast
aaab
pattern
caus
bresidu
spiral
around
helix
axi
two
b
residu
contribut
key
hydrophob
contact
cleft
eg
b
b
substitut
cyclic
constrain
bresidu
acpc
apc
sapc
fig
acycl
b
residu
almost
systemat
improv
bind
abpeptid
bclx
l
interestingli
highli
select
ligand
either
bclx
l
obtain
introduc
b
bcyclic
residu
replac
either
two
bresidu
posit
make
contact
protein
eg
b
acpc
caus
increas
furthermor
global
b
cyclic
bresidu
replac
sequenc
result
potent
ligand
bclx
l
enhanc
protect
activ
proteas
halflif
greater
cognat
apeptid
presenc
proteinas
k
approach
cyclic
bresidu
replac
combin
introduct
hydrocarbon
stapl
adisubstitut
pentenylcontain
amino
acid
give
helix
mimic
exhibit
remark
resist
proteas
degrad
recapitul
function
parent
stapl
peptid
abil
enter
differ
type
cell
engag
antiapoptot
protein
target
kill
lymphoma
cell
smaller
nonhel
foldam
append
side
chain
mimick
key
hydrophob
side
chain
well
conserv
carboxyl
peptid
design
target
proapoptot
famili
member
molecul
base
terphenyl
triazinepiperazinetriazin
scaffold
report
bind
bclx
l
fluoresc
polar
assay
k
low
mm
submm
rang
potent
compound
worth
mention
compound
terphenyl
seri
show
select
lower
bind
unrel
target
like
section
interact
signific
effort
toward
ahelix
mimicri
concentr
mous
interact
import
target
cancer
therapi
tumor
suppressor
transcript
factor
activ
cell
death
respons
variou
stress
condit
dna
damag
hypoxia
protein
neg
regul
doubleminut
protein
overexpress
cancer
directli
contribut
tumor
develop
progress
inhibit
interact
restor
wildtyp
activ
tumor
overexpress
potenti
strategi
cancer
treatment
xray
crystallographi
complex
reveal
upon
bind
activ
domain
adopt
helic
conform
three
residu
one
face
helix
form
hydrophob
patch
buri
bind
caviti
sinc
earli
report
highlight
structur
base
interact
differ
class
homolog
also
inactiv
antagonist
develop
potenti
anticanc
agent
rang
lowmolecularweight
compound
peptid
semin
paper
focus
short
peptid
encompass
residu
research
novarti
demonstr
benefit
stabil
ahel
conform
achiev
effect
inhibit
interact
peptidebas
approach
aim
stabil
helix
improv
bind
sinc
flourish
introduct
adialkyl
residu
side
chain
crosslink
hydrogen
bond
surrog
hb
well
use
miniprotein
scaffold
design
artifici
oligomer
scaffold
abil
reproduc
project
key
hydrophob
side
chain
concurr
develop
salt
bridgestabil
bpeptid
bear
residu
one
face
helix
b
leu
b
trp
analog
b
phe
ii
relationship
investig
possibl
mimic
potent
bpeptid
abil
bind
hdmx
nanomolar
rang
subsequ
obtain
use
computeraid
optim
replac
central
indol
side
chain
aromat
moieti
two
approach
subsequ
explor
improv
cell
permeabl
helic
bpeptid
cationicpatch
insert
hydrocarbon
side
chain
bridg
variant
minim
cation
motif
embed
one
face
saltbridg
face
bpeptid
shown
bind
equal
well
taken
cell
effici
equal
prr
control
cpp
approach
could
avoid
attach
extra
arg
rich
cellpenetr
sequenc
see
section
cell
penetr
foldam
intracellular
drug
deliveri
membran
disrupt
would
significantli
increas
molecular
mass
deriv
analog
stapl
peptid
may
increas
cell
uptak
bpeptid
analog
contain
diether
hydrocarbon
stapl
also
prepar
bpeptid
bridg
posit
eg
found
bind
slightli
better
importantli
taken
cell
effici
correspond
unbridg
peptid
worth
mention
foldam
approach
also
compat
ahelixstabil
technolog
hb
approach
arora
cowork
design
conform
stabl
peptid
analog
combin
beta
amino
acid
replac
aaab
backbon
pattern
hb
cap
equal
potent
correspond
hbstermin
apeptid
bind
recombin
eg
k
ae
ae
nm
respect
fig
highaffin
low
nanomolar
rang
proteolyt
stabl
helic
lefthand
dpeptid
ligand
identifi
mirror
imag
phage
display
highresolut
structur
analysi
one
peptid
ie
daspdtrpdtrpdprodleudaladphedgludaladleudleudarg
k
nm
complex
pdb
id
fig
suggest
aromat
side
chain
residu
fulli
fill
correspond
bind
caviti
suggest
rational
enhanc
bind
peptid
ligand
introduct
substitu
para
posit
sequenc
relat
peptid
found
enhanc
bind
mdmx
paratrifluoromethyl
substitut
effect
daladtrpdtyrdaladasndph
dgludlysdleudleudarg
k
nm
sprbase
competit
bind
assay
crystal
structur
complex
solv
resolut
pdb
id
indic
paratrifluoromethyl
enlarg
total
buri
surfac
area
dpeptid
complex
also
suggest
ligand
improv
modif
side
chain
fig
introduct
fluorin
atom
posit
indol
ring
led
activ
compound
k
pm
one
limit
dapeptid
poor
capac
transloc
across
cell
membran
thu
engag
mdmx
insid
cell
cytotox
observ
cell
line
mm
would
requir
implement
addit
strategi
conjug
molecular
transport
see
section
cell
penetr
foldam
intracellular
drug
deliveri
membran
disrupt
foldam
target
intracellular
ppi
varieti
inhibitor
interact
base
extend
rel
rigid
scaffold
report
see
fig
earli
work
aromat
terphenyl
scaffold
substitut
three
ortho
posit
aryl
alkyl
group
mimick
hotspot
residu
posit
helix
demonstr
abil
topograph
mimic
engag
select
target
vitro
fluorescencebas
assay
n
hsqc
perturb
shift
experi
remark
sever
compound
seri
exemplifi
shown
inhibit
ppi
submicromolar
concentr
select
ppi
similar
type
bind
interfac
bclx
l
bak
bak
select
respect
surprisingli
select
compound
revers
substitut
moieti
see
section
target
antiapoptot
famili
member
remark
sever
terphenyl
mimet
found
membran
permeabl
induc
accumul
activ
tumor
cell
elabor
led
aromat
scaffold
heteroatom
oligopyridylamid
oligobenzamid
whose
solubl
improv
terphenyl
backbon
synthesi
modular
transfer
solidphas
amen
creation
larger
librari
inhibitor
low
mm
rang
report
screen
focus
librari
divers
substitut
nalkyl
oligobenzamid
exemplifi
well
hybrid
oligoamid
contain
singl
multipl
proteinogen
aamino
acid
replac
select
posit
exemplifi
compound
abil
interfer
interact
cell
report
includ
potent
membraneperm
dual
inhibitor
eg
interact
compound
increas
prefer
obtain
substitut
proteinogen
amino
acid
residu
central
amino
benzoic
acid
unit
result
select
ie
vs
influenc
stereochemistri
aamino
acid
residu
similar
fashion
aliphat
oligooxopiperazin
also
evalu
possibl
ahelix
mimic
comput
design
use
rosetta
softwar
http
wwwrosettacommonsorg
modifi
enabl
model
oxopiperazin
combin
experiment
relationship
data
led
discoveri
inhibitor
eg
k
mm
rosettaderiv
model
complex
support
h
n
hsqc
nmr
titrat
experi
figur
inhibitor
interact
base
extend
rigid
ahelix
mimet
scaffold
transcript
factor
involv
ahel
interfac
also
target
helix
mimet
play
crucial
role
adapt
tumor
cell
hypoxia
hypoxia
asubunit
accumul
dimer
constitut
express
aryl
hydrocarbon
receptor
nuclear
transloc
subunit
recruit
coactiv
crebbind
protein
via
transactiv
domain
exert
transcript
role
hypoxiarespons
target
gene
play
key
role
cancer
biolog
angiogenesi
invas
metastasi
coactiv
interact
repres
possibl
target
control
hypoxia
signal
solut
structur
complex
pdb
id
reveal
ctermin
transactiv
domain
bind
domain
via
three
short
helic
region
extens
network
hydrophob
polar
interact
fig
arora
cowork
report
oligooxopiperazin
deriv
design
mimic
side
chain
display
three
four
residu
third
helix
make
close
contact
domain
name
particular
compound
found
bind
domain
affin
nm
downregul
multipl
gene
implic
angiogenesi
apoptosi
cell
prolifer
invas
nonsmallcel
lung
cancer
cell
line
activ
vivo
see
section
vivo
studi
bioactiv
foldam
optim
compound
led
oligooxopiperazin
exhibit
enhanc
bind
affin
specif
target
surfac
similar
fashion
oligobenzamid
design
mimic
third
helix
report
inhibit
bind
peptid
fluoresc
anisotropi
competit
assay
activ
mm
rang
eg
ic
mm
result
obtain
short
helix
mimet
signific
given
parent
peptid
encompass
third
helix
activ
potenti
use
extens
approach
improv
activ
short
topograph
mimic
term
affin
andor
target
specif
combin
helix
mimet
rest
nativ
peptid
sequenc
singl
extend
hybrid
molecul
one
exampl
report
wilson
group
hybrid
molecul
consist
second
helix
link
molecul
although
result
compound
show
improv
bind
compar
nativ
sequenc
result
molecul
exhibit
much
increas
specif
target
compar
interest
direct
may
lead
target
peptid
sequenc
longer
composit
protein
new
properti
worth
continu
explor
vascular
endotheli
growth
factor
vegf
key
mediat
angiogenesi
vasculogenesi
whose
biolog
effect
mediat
two
receptor
tyrosin
kinas
import
role
vegf
tumor
angiogenesi
make
import
therapeut
target
vegf
antagonist
receiv
consider
attent
context
cancer
therapi
bevacizumab
recombin
human
monoclon
antibodi
block
angiogenesi
inhibit
interact
cell
surfac
receptor
aflibercept
recombin
fusion
protein
consist
extracellular
domain
ecd
human
vegf
receptor
approv
drug
treat
cancer
macular
degener
phage
display
method
employ
identifi
disulfideconstrain
peptid
well
mini
protein
eg
deriv
threehelix
zdomain
scaffold
bind
receptorbind
domain
residu
vegf
antagon
bind
vegf
receptor
haas
et
al
investig
b
replac
cyclic
vegfbind
peptid
dual
aim
increas
resist
proteolysi
maintain
affin
vegf
regular
pattern
b
replac
aabaaab
aaab
result
compound
low
bind
profil
probabl
due
absenc
welldefin
regular
helic
conform
parent
peptid
nevertheless
sever
abhybrid
contain
three
six
breplac
found
retain
signific
affin
vegf
albeit
lower
affin
rel
parent
peptid
display
increas
resist
anoth
studi
checco
et
al
start
threehelix
zdomain
scaffold
vegf
ligand
zvegf
simplifi
remov
one
helic
segment
constrain
introduc
disulfid
crosslink
end
loop
result
dimer
bind
vegf
affin
zvegf
serv
start
point
implement
b
replac
within
helic
segment
introduct
six
bresidu
site
contact
target
protein
interfer
tertiari
pack
led
abpeptid
structur
function
mimic
bind
surfac
parent
peptid
affin
rang
slightli
improv
exhibit
significantli
increas
resist
proteolysi
rel
cognat
apeptid
proteinas
k
assay
crystal
structur
tightest
vegfbind
abpeptid
complex
vegf
pdb
id
confirm
bind
surfac
vegf
zvegf
pdb
id
http
anticip
helixloophelix
conform
see
fig
addit
found
attenu
vegfinduc
prolifer
human
umbil
vein
endotheli
cell
noteworthi
b
replac
approach
also
success
extend
produc
effect
mimic
zdomainderiv
peptid
bind
target
protein
tumor
necrosi
factora
proinflammatori
cytokin
involv
sever
inflammatori
diseas
fc
portion
human
mirror
imag
phage
display
use
kent
collabor
engin
highaffin
mini
dprotein
ligand
vegf
lform
block
bind
vegf
cognat
receptor
use
domain
streptococc
protein
g
scaffold
display
design
divers
librari
mutant
screen
synthet
dvegf
follow
round
affin
matur
highresolut
xray
structur
heterochir
lvegfdprotein
antagonist
complex
determin
racem
protein
crystallographi
pdb
id
http
http
detail
analysi
interact
dprotein
antagonist
vegfa
reveal
bind
interfac
local
region
vegf
interact
plasma
stabil
pk
immunogen
mini
dprotein
studi
detail
evalu
potenti
dprotein
therapeut
agent
see
section
antigen
immunogen
bioactiv
foldam
approach
discuss
previou
section
helic
mimick
viral
glycoprotein
inhibit
viral
fusion
foldamerbas
inhibitor
ppi
link
cancer
recent
extend
creat
analog
peptid
hormon
ligand
class
b
gproteincoupl
receptor
gpcr
includ
secretin
glucagon
glucagonlik
peptid
glucosedepend
insulinotrop
polypeptid
gip
vasoact
intestin
peptid
vip
corticotrophinreleas
factor
crf
parathyroid
hormon
pth
growth
hormonereleas
factor
pituitari
adenyl
cyclaseactiv
peptid
pacap
calcitonin
although
gener
unfold
aqueou
solut
cterminu
natur
ligand
class
b
gpcr
adopt
ahel
structur
upon
bind
cognat
receptor
endogen
peptid
ligand
class
b
secretin
receptor
famili
gpcr
synthet
deriv
attract
consider
interest
candid
treatment
sever
human
patholog
sever
market
drug
eg
liraglutid
teriparatid
signific
insight
mechan
class
b
gpcr
activ
provid
structur
analys
ecd
sever
receptor
includ
pacap
gip
receptor
complex
bound
peptid
ligand
natur
ligand
analog
first
structur
membranespan
domain
gpcr
structur
ecd
bound
peptid
ligand
peptid
adopt
amphipath
ahel
conform
hydrophob
side
chain
buri
groov
surfac
ecd
ctermin
residu
contact
ecd
ntermin
end
protrud
ecd
crystallograph
data
set
suggest
twostep
mechan
wherebi
interact
ecd
cterminu
peptid
hormon
expos
ntermin
part
transmembran
domain
receptor
extens
effort
made
last
decad
stabil
ahel
conform
lifetim
biolog
fluid
peptid
hormon
gener
potent
agonist
antagonist
chemic
approach
base
introduct
adialkyl
amino
acid
side
chain
crosslink
larg
employ
recent
gellman
cowork
shown
care
design
abpeptid
also
produc
effect
mimic
class
b
gpcr
ligand
increas
resist
proteolyt
degrad
possibl
abil
modul
receptor
signal
first
studi
examin
six
analog
pth
full
agonist
human
pth
receptor
activ
ingredi
osteoporosi
drug
teriparatid
analog
contain
five
seven
b
replac
extend
cterminu
aaab
pattern
six
abpeptid
prove
full
agonist
monitor
camp
product
cell
stabli
express
remark
contain
seven
b
replac
indistinguish
pth
term
affin
agonist
potenc
compound
display
vivo
activ
see
also
section
ab
peptid
analog
class
b
gpcr
agonist
similar
period
b
replac
sequenc
relat
dtrp
pth
found
retain
antagonist
invers
agonist
activ
apeptid
increas
resist
proteolyt
degrad
sharp
contrast
even
fewer
b
replac
sequenc
glucagonlik
peptid
nh
display
full
activ
receptor
result
consider
loss
activ
measur
camp
product
ec
nm
compar
ec
nm
nh
agonist
activ
receptor
restor
introduc
ringconstrain
bamino
acid
acpc
apc
compound
contain
five
b
replac
prove
full
agonist
nativ
potenc
nh
short
plasma
halflif
min
rapidli
degrad
proteas
dipeptidyl
specif
cleav
neprilysin
nep
cleav
although
b
replac
expect
suppress
action
nep
larg
extent
attempt
extend
b
modif
toward
nterminu
provid
stabil
found
detriment
activ
compound
analog
two
aib
residu
posit
found
full
agonist
highli
resist
vitro
degrad
abpeptid
found
promot
glucosestimul
insulin
secret
freshli
isol
mous
islet
dosedepend
manner
similar
activ
vivo
glucos
toler
test
gtt
see
section
ab
peptid
analog
class
b
gpcr
agonist
fig
b
replac
strategi
also
appli
vip
improv
resist
proteolysi
vip
elicit
immunebas
neuroprotect
short
halflif
hamper
possibl
therapeut
applic
furthermor
vip
activ
two
broadli
distribut
receptor
interest
analog
would
display
receptor
select
two
metabol
stabl
agonist
develop
exampl
compound
contain
nine
b
substitut
either
nativ
side
chain
constrain
residu
potent
agonist
highli
select
versu
exhibit
strong
resist
proteinas
activ
pepsin
proteinas
k
chymotrypsin
two
peptid
investig
abil
protect
mice
mptp
induc
neurodegener
use
model
parkinson
diseas
pd
see
section
ab
peptid
analog
class
b
gpcr
agonist
misfold
aggreg
amyloid
protein
implic
patholog
rang
diseas
alzheim
diseas
type
diabet
pd
foldam
approach
base
bsheet
helix
mimic
employ
antagon
aggreg
variou
amyloid
protein
potenti
reduc
toxic
amyloid
aggreg
nowick
cowork
focus
amyloidb
ab
sheet
mimic
absm
display
abstrand
differ
amyloid
protein
includ
abpeptid
associ
alzheim
diseas
tau
human
yeast
prion
protein
human
human
asynuclein
associ
pd
human
islet
amyloid
polypeptid
iapp
associ
type
diabet
particular
design
ring
macrocycl
bsheet
fig
compris
recognit
amyloid
heptapeptid
fragment
upper
strand
could
bind
parent
amyloid
protein
one
hao
unit
serv
tripeptid
bstrand
mimic
lower
strand
two
flank
dipeptid
promot
intramolecular
hbond
two
dlink
ornithin
orn
residu
connect
two
strand
hao
unit
play
addit
role
prevent
absm
aggreg
solut
form
infinit
network
bsheet
minim
expos
hbond
group
lower
strand
remark
absm
ab
upper
strand
found
delay
aggreg
ab
monitor
thioflavin
fluoresc
assay
transmiss
electron
microscopi
tem
substoichiometr
concentr
low
mm
reduc
toxic
cell
current
model
absm
thu
bind
earli
bstructur
oligom
monom
block
abnucl
shortlength
aromat
foldam
consist
aromat
salicylamid
sal
benzoic
acid
benz
backbon
contain
basic
arginin
arg
lysin
ly
citrullin
cit
side
chain
also
report
prevent
spontan
seed
abfibril
mirank
cowork
focus
inhibit
membranebound
oligomer
intermedi
amyloidogen
iapp
hormon
peptid
hypothes
contribut
bcell
patholog
type
diabet
fig
identifi
oligopyridin
ahelix
mimet
oligoquinolin
helic
foldam
stabil
preamyloid
ahel
conform
iapp
inhibit
lipidcatalyz
iapp
aggreg
oligoquinolin
water
solubl
cross
biolog
membran
found
rescu
bcell
iappinduc
toxic
upon
coaddit
iapp
also
remark
time
delay
h
introduc
addit
iapp
addit
cell
fig
much
effort
devot
discoveri
molecular
transport
conjug
molecul
interest
eg
drug
peptid
protein
dna
might
facilit
entri
cell
cation
peptid
deriv
tat
drosophila
antennapedia
mani
protein
transloc
cell
membran
mediat
deliveri
cargo
molecul
target
cell
knowledg
cellpenetr
sequenc
stimul
design
wide
rang
cell
penetr
peptid
cpp
larg
fraction
arginin
rich
guanidinium
headgroup
play
crucial
role
cell
entri
process
concurr
approach
base
nonnatur
oligomer
backbon
includ
foldam
may
provid
new
class
molecular
transport
ie
cellpenetr
foldam
cpf
improv
stabil
biolog
fluid
exampl
oligom
darg
eg
well
mix
ldoctaarginin
display
cellpenetr
properti
compar
even
greater
control
tat
peptid
togeth
increas
enzymat
metabol
resist
similarli
guanidinerich
peptoid
apeptidebpeptoid
chimera
oligocarbam
oligom
aaminoxi
acid
shown
equal
even
potent
enter
cell
correspond
lpeptid
molecul
adopt
regular
structur
solut
provid
evid
defin
conform
strictli
requir
apeptid
peptoid
transloc
across
cell
membran
similarli
short
polycation
bpeptid
includ
b
hargb
hli
oligom
rapidli
enter
cytoplasm
nucleu
human
cell
extracellular
medium
endocytosi
although
b
peptid
show
strong
conform
prefer
aqueou
environ
howev
larg
helic
meoh
solut
presenc
lipid
micel
subsequ
studi
shown
conform
stabil
bpeptid
geometri
guanidinium
group
display
directli
affect
entri
live
cell
exampl
achccontain
bpeptid
form
stabl
helix
aqueou
solut
found
enter
hela
cell
greater
extent
cognat
b
peptid
lower
helixform
propens
similar
trend
observ
abpeptid
analog
tat
introduct
cyclic
bamino
acid
bear
side
chain
guanidinium
group
led
cpf
substanti
helic
methanol
enter
hela
cell
much
readili
correspond
tat
apeptid
b
argcontain
abpeptid
introduct
minim
cation
motif
one
face
bioactiv
helic
bpeptid
eg
ppi
inhibitor
yet
anoth
approach
increas
cellular
entri
avoid
conjug
extra
cpp
cpf
fig
bioreduc
helic
cpf
high
capac
assembl
plasmid
dna
deliv
nucleic
acid
cell
obtain
thiolmedi
dimer
short
amphipath
helic
oligourea
bear
arg
side
chain
compound
found
compar
favor
term
transfect
effici
hisrich
peptid
cpp
high
transfect
abil
mention
previou
section
inhibitor
amyloid
protein
aggreg
fibrillik
oligom
assembl
format
aromat
oligoamid
foldam
may
also
display
uniqu
cellpenetr
properti
huc
cowork
shown
helic
fold
aromat
oligoamid
peripher
cation
side
chain
abl
effici
cross
cell
membran
report
cell
entri
depend
length
number
posit
charg
aromat
foldam
octam
prove
activ
cpf
three
test
cell
line
ii
mediat
endocytosi
like
cpp
synthet
oligoamid
attract
consider
attent
nucleic
acid
analog
pna
analog
bdna
minor
groov
binder
hairpin
pyim
polyamid
repres
interest
candid
applic
biolog
therapeut
agent
see
section
fold
upon
bind
pna
use
extens
tool
specif
modul
gene
express
target
translat
transcript
process
develop
drug
suffer
low
cellular
uptak
limit
water
solubl
although
techniqu
may
use
overcom
drawback
eg
cpp
pyim
polyamid
bind
defin
dna
sequenc
affin
specif
compar
dnabind
protein
may
induc
alloster
chang
dna
helix
interfer
dna
bind
transcript
factor
eg
hypoxiainduc
factor
alpha
nuclear
factor
kappa
b
pyim
polyamid
fig
use
molecular
probe
cell
cultur
alter
gene
express
profil
recent
studi
turn
anim
model
pyim
polyamid
show
toxic
varieti
cancer
cell
line
see
section
vivo
studi
bioactiv
foldam
although
literatur
nucleic
acid
recognit
artifici
oligom
far
domin
pna
numer
analog
pyim
polyamid
new
fold
backbon
helic
aromat
amid
foldam
report
bind
dna
target
gquadruplex
dna
helic
oligoamid
base
acid
bear
cation
side
chain
tetram
select
interact
dna
gquadruplex
solut
includ
human
telomer
gquadruplex
htelo
quadruplex
sequenc
sever
gene
promot
eg
cmyc
kra
specif
interact
support
fact
direct
dna
evolut
studi
relat
longer
helic
cation
oligoamid
identifi
gquadruplex
prefer
target
wherea
known
gquadruplex
ligand
flat
aromat
structur
stack
top
gtetrad
helic
shape
quinolinebas
oligoamid
make
similar
mode
interact
unlik
recent
cocryst
structur
antiparallel
hairpin
dimer
dna
gquadruplex
g
g
support
bind
mode
driven
ammoniumphosph
electrostat
interact
foldam
cation
side
chain
dna
backbon
loop
fig
resolut
select
foldam
gquadruplex
interact
like
guid
ration
design
potent
aromat
helic
foldamerbas
ligand
dna
gquadruplex
synthet
foldam
made
unnatur
backbon
intrins
differ
chemic
structur
natur
apeptid
biopolym
intend
mimic
differ
gener
assess
vitro
term
interact
biolog
target
resist
proteolysi
membran
permeabl
cellular
activ
see
previou
section
rel
studi
focus
activ
foldam
vivo
context
develop
possibl
therapeut
applic
increas
interest
know
properti
foldam
vivo
efficaci
anim
model
durat
action
pk
toxic
immunogen
along
increas
resist
proteolyt
degrad
see
section
resist
proteolysi
foldam
mimic
natur
peptid
like
manifest
differ
pk
result
differ
activ
vivo
limit
number
studi
examin
pk
properti
tissu
distribut
bioactiv
foldam
larg
extent
investig
focus
cation
amphiphil
helic
residu
long
antibacteri
activ
known
name
antibacteri
b
h
b
alab
lysb
phe
oh
peptoid
analog
n
n
link
oligourea
well
b
arg
cation
cpf
pk
studi
doubli
clabel
h
b
alab
lysb
phe
oh
deriv
rat
reveal
follow
intraven
iv
administr
mg
kg
concentr
bpeptid
blood
plasma
decreas
rapidli
radioact
distribut
organ
tissu
ii
day
residu
radioact
organ
tissu
repres
iv
dose
high
level
kidney
lymph
node
liver
iii
bpeptid
highli
stabl
metabol
degrad
vivo
neglig
absorpt
took
place
per
os
administr
administ
dose
complet
excret
via
fece
within
h
trend
observ
follow
iv
administr
clabel
b
arg
deriv
excret
bodi
even
slower
dose
day
major
fraction
radioact
end
liver
dose
still
found
liver
h
postdos
peptoid
analog
conjug
assay
vivo
culabel
dota
biodistribut
studi
smallanim
positron
emiss
tomographi
pet
iv
administr
biodistribut
studi
culabel
peptoid
demonstr
promin
uptak
liver
slow
elimin
liver
region
observ
pet
imag
pk
profil
tissu
distribut
hlabel
analog
investig
betaradio
imag
wholebodi
map
mice
follow
intranas
administr
larg
amount
radioact
sequest
transient
within
lung
upper
airway
low
excret
recoveri
oligourea
kidney
follow
iv
inject
found
consist
high
stabil
vivo
overal
observ
vivo
stabil
high
tissu
uptak
consist
two
studi
conduct
bpeptid
peptoid
like
reflect
specif
featur
compound
proteas
resist
membran
permeabl
cation
foldam
remain
seen
whether
pk
biodistribut
properti
report
specif
foldam
modul
upon
sequenc
variat
whether
similar
trend
would
observ
fold
backbon
much
inform
also
gain
pk
toxic
pyim
polyamid
rodent
pyim
polyamid
cellperm
molecul
depend
architectur
circul
sever
hour
iv
administr
h
case
number
studi
document
activ
vivo
without
evid
system
toxic
exampl
polyamid
design
target
consensu
androgen
glucocorticoid
respons
element
w
capabl
traffick
tumor
site
follow
subcutan
inject
modul
transcript
select
gene
vivo
fitclabel
version
polyamid
detect
tumorderiv
cell
confoc
microscopi
compound
demonstr
efficaci
vivo
prostat
cancer
xenograft
mice
limit
toxic
c
case
foldam
mimick
host
defens
peptid
see
section
membran
activ
foldam
antimicrobi
evalu
mous
model
bacteri
infect
exampl
arylamid
foldam
develop
degrado
found
exhibit
signific
activ
aureu
thigh
infect
model
thigh
muscl
neutropen
mice
inocul
bacteria
follow
iv
administr
foldam
administ
dose
mg
kg
ie
reduct
viabl
cfu
aureu
atcc
today
famili
foldam
probabl
advanc
term
clinic
develop
brilacidin
close
analog
origin
develop
polymedix
new
class
antibiot
sinc
cellceutix
http
cellceutixcom
recent
complet
phase
clinic
trial
treatment
acut
bacteri
skin
skin
structur
infect
caus
aureu
includ
mrsa
trial
brilacidin
demonstr
high
clinic
respons
rate
compar
daptomycin
activ
control
shown
safe
gener
welltoler
fig
longer
analog
peptoid
recent
test
vivo
use
murin
model
invas
aureu
bacteri
challeng
concentr
mg
kg
compound
appar
caus
mediumterm
toxic
treatment
concentr
result
averag
twologord
reduct
bacteri
count
peritonium
moreov
mortal
reduc
peptoidtr
group
compar
salinetr
control
anoth
studi
n
n
link
oligourea
activ
vitro
bacteri
form
b
anthraci
encount
vivo
ie
germin
spore
encapsul
nonencapsul
bacilli
evalu
cutan
inhal
model
infect
b
anthraci
model
infect
highli
inform
infecti
process
develop
natur
rout
normocompet
mice
without
immun
manipul
compound
found
exert
protect
activ
vivo
cutan
model
infect
limit
local
treatment
increas
time
surviv
led
partial
protect
similar
delay
time
death
also
observ
follow
inhal
infect
sever
studi
report
vivo
activ
abpeptid
ligand
class
b
gpcr
receptor
mention
section
ligand
gproteincoupl
receptor
hormon
like
analog
agonist
test
gtt
abil
normal
circul
glucos
level
follow
administr
bolu
glucos
mice
inject
abpeptid
nh
mg
kg
equal
effect
suppress
rise
blood
glucos
concentr
rel
vehicletr
mice
gtt
furthermor
gtt
repeat
h
agonist
administr
glucoselow
effect
maintain
nh
overal
result
possibl
reflect
higher
resist
abpeptid
proteolysi
show
b
replac
strategi
effect
gener
potent
bfamili
gpcr
agonist
recapitul
hormon
function
vivo
could
find
use
biomed
applic
support
vivo
studi
agonist
subcutan
inject
abpeptid
agonist
induc
calcem
respons
mice
longer
caus
pth
correl
well
affin
particular
function
state
receptor
ie
r
state
form
independ
g
heterotrimer
gprotein
respons
activ
adenyl
cyclas
upon
receptor
activ
calcem
effect
durat
like
facilit
substanti
prolong
bloodstream
bioavail
deriv
compar
pth
develop
longact
pth
analog
may
find
practic
use
treat
hypoparathyroid
agent
normal
blood
calcium
level
extend
period
continu
need
abpeptid
agonist
test
abil
protect
mice
mptpinduc
neurodegener
use
model
pd
metabol
stabl
agonist
display
improv
vivo
pk
profil
min
comparison
previous
report
vip
min
found
effect
immunomodulatori
agent
diseaserelev
pd
model
treatment
mptpintox
mice
significantli
spare
dopaminerg
neuron
cell
bodi
decreas
amount
reactiv
microgliosi
downregul
proinflammatori
cytokin
product
modul
tcell
phenotyp
treatment
contrast
treatment
stabl
agonist
yield
lesser
neuroprotect
respons
result
support
use
agonist
neuroprotect
agent
pd
treatment
overal
three
studi
demonstr
abpeptid
approach
particularli
well
suit
mimic
long
peptid
helic
increas
biolog
lifetim
natur
peptid
hormon
remain
seen
whether
type
foldam
backbon
could
equal
use
design
ligand
class
b
gpcr
exampl
foldam
design
modulateinhibit
intracellular
ppi
actual
display
intrins
capac
cross
cell
membran
reach
appropri
locat
insid
cell
engag
target
protein
rel
spars
domin
topograph
mimic
oligooxopiperazin
design
mimic
target
transcript
coactiv
one
exampl
compound
shown
activ
mous
tumor
xenograft
model
inject
mg
kg
mice
bear
xenograft
deriv
tripleneg
breast
cancer
cell
line
reduc
median
tumor
volum
roughli
compar
untreat
group
without
show
measur
chang
anim
bodi
weight
fold
aliphat
backbon
dpeptid
aliphat
band
abpeptid
helic
may
endow
cellpenetr
properti
sequenc
variat
side
chain
crosslink
conjug
molecular
transport
case
dpeptid
ligand
despit
biostabl
effect
bind
fail
activ
penetr
cell
particular
case
conjug
cellpenetr
sequenc
darg
via
cterminu
lead
expect
activ
result
necrosi
cell
line
manner
howev
dpeptid
ligand
either
free
form
palmityl
shown
kill
human
glioblastoma
cell
manner
exert
antitumor
activ
nude
mous
xenograft
model
encapsul
liposom
function
integrintarget
cyclicrgd
peptid
thu
provid
proof
principl
effici
dpeptid
load
deliveri
character
possibl
interact
biolog
relev
foldam
immun
system
make
sure
induc
unwant
immun
respons
host
import
issu
certainli
need
care
address
therapeut
applic
sought
date
still
littl
inform
avail
possibl
immunogen
foldam
recognit
special
molecul
immun
system
antibodi
major
histocompat
complex
mhc
molecul
tcell
receptor
earli
work
report
immun
respons
nonnatur
peptid
backbon
eg
dpeptid
often
result
effort
make
effect
immunogen
conjug
carrier
protein
andor
associ
adjuv
studi
investig
role
peptid
backbon
cell
recognit
scan
backbon
antigen
peptid
pseudopeptid
bond
singl
b
replac
measur
capac
pseudopeptid
bind
cognat
mhc
molecul
subsequ
engag
cell
receptor
tcr
complet
differ
object
ie
avoid
immun
respons
gellman
cowork
investig
bioactiv
abpeptid
eg
bim
deriv
high
b
residu
content
regular
pattern
eg
aaab
aabaaab
recogn
immun
system
compar
cognat
apeptid
turn
recognit
antibodi
rais
prototyp
apeptid
suppress
period
b
replac
antibodi
rais
abpeptid
fail
recogn
prototyp
apeptid
display
ident
side
chain
repertoir
final
period
b
replac
cell
viral
epitop
suppress
format
product
mhc
ipeptidetcr
ternari
complex
would
activ
cytotox
tlymphocyt
due
part
disrupt
mhc
bind
although
studi
need
determin
whether
lack
crossreact
homolog
apeptid
foldam
gener
featur
data
support
recent
analysi
small
dprotein
scaffold
select
bind
vegfa
complet
resist
proteolysi
mous
monkey
human
plasma
longer
vivo
halflif
cognat
lprotein
inject
iv
complet
lack
immunogen
even
dose
combin
strong
adjuv
advanc
foldam
chemistri
togeth
find
nonnatur
oligomer
backbon
may
retain
fold
water
exhibit
diminish
suscept
degrad
proteas
gave
impetu
use
synthet
fold
oligom
mani
differ
biolog
therapeut
relev
context
structur
mimic
amp
inhibitor
ppi
peptid
hormon
mimic
dna
ligand
remark
progress
made
field
sinc
semin
discoveri
short
bpeptid
may
adopt
welldefin
helic
secondari
structur
akin
found
protein
sequencebas
biopolym
mimicri
still
greater
role
play
pharmacolog
tool
possibl
toward
develop
innov
mediums
therapeut
agent
use
foldam
protein
secondari
structur
mimic
modul
biolog
interact
current
domin
aliphat
oligom
abpeptid
robust
gener
design
principl
propos
mani
new
backbon
biotic
abiot
current
avail
evalu
expand
scope
possibl
approach
address
particular
biolog
question
structur
character
high
resolut
foldamerbiopolym
interact
molecular
model
tool
becom
increasingli
import
learn
precis
foldam
interact
biolog
surfac
mimic
inform
encod
biopolym
guid
design
potent
bioactiv
foldam
studi
report
activ
foldam
vivo
pk
properti
foldam
anim
model
still
rare
direct
sure
develop
futur
contribut
address
import
issu
pk
tissu
distribut
toxic
immunogen
practic
develop
uniqu
fascin
class
molecul
